Aurora Cannabis

Aurora Cannabis Q2 2017 Results Visualized

Operational Highlights and Recent Developments


Revenues of $3.9 million, as compared to $0 (nil) for Q2 2016.  Q2 2017 revenues reflect 26.5% sequential growth over Q1 2017. Current sales pace exceeds $1.5 million per month. The Company continues to execute well on all aspects of its growth strategy through the construction of a state-of-the-art 800,000 square foot production facility, as well as continued investments in technology, innovation, partnerships, customer service, and sales and marketing.

News Recap


  • On January 16, 2017, the Company initiated a voluntary recall of products purchased from another licensed producer for resale purposes, which the Company had found to contain a pesticide not currently registered for use on medical cannabis.


  • The licensed producer that had sold the recalled cannabis to Aurora has agreed to fully reimburse the Company as follows:
    • A cash payment in the amount of $384,835, constituting a full refund for product returned, and
    • A credit in the amount of approximately $450,000, fully covering Aurora’s costs incurred via extension of purchase credits by Aurora to its affected clients.


  • Signed a Memorandum of Understanding with Radient Technologies Inc. (“Radient”) for the joint development and commercialization of superior and standardized cannabinoid extracts at high throughputs.


  • Invested in Radient by way of a $2,000,000 10% convertible debenture. Additionally, announced the intention to participate in Radient’s private placement financing of up to $1,250,000 units at $0.45 per unit.




A message from management to shareholders 

“The Aurora team continues to exceed its very aggressive strategic goals set out and approved by its board of directors,” said Terry Booth, CEO. “We are serving our rapidly growing base of active registered patients with some of the best cannabis on the market, and we continue to enrich the customer experience with innovations such as our hugely popular mobile app. We are also building a truly exceptional new 800,000 square foot state-of-the-art production facility, which we believe differentiates us and positions us exceptionally well to capitalize on the numerous opportunities created both by the rapidly growing medical cannabis market and the adult consumer market, once legalization is implemented. Additionally, initiatives such as our collaboration with Radient Technologies Inc. to research and implement superior extraction techniques, are indicative of how Aurora continues to be at the forefront of development in the sector. With one of the strongest cash positions in the industry, we are extremely well capitalized to execute on all our strategic growth plans, including the construction of our new Aurora Sky facility.”

About the author


Leave a Comment